{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:55:37Z","timestamp":1768272937811,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101102733\\u2014DURABLE"],"award-info":[{"award-number":["101102733\\u2014DURABLE"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.vaccine.2025.127871","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:20:41Z","timestamp":1761182441000},"page":"127871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Modelling the impact of a quadrivalent ACWY meningococcal vaccination and vaccination targeting serogroup B in France"],"prefix":"10.1016","volume":"67","author":[{"given":"Paolo","family":"Bosetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laur\u00e8ne","family":"Peckeu-Abboud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland Michel","family":"Andrianasolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Baguelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Fonteneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ala-Eddine","family":"Deghamne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhamed-Kheir","family":"Taha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Sophie","family":"Barret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Grimprel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lulla","family":"Opatowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"L\u00e9vy-Bruhl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Cauchemez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127871_bb0005","doi-asserted-by":"crossref","first-page":"e582","DOI":"10.1016\/S2589-7500(23)00108-5","article-title":"Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS consortium","volume":"5","author":"Shaw","year":"2023","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.vaccine.2025.127871_bb0010","series-title":"Infections invasives \u00e0 m\u00e9ningocoque en France en 2023. [cited 3 Mar 2025]","author":"SPF","year":"2025"},{"key":"10.1016\/j.vaccine.2025.127871_bb0015","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1186\/s12879-024-09547-y","article-title":"Recent increase in atypical presentations of invasive meningococcal disease in France","volume":"24","author":"Taha","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127871_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/23744235.2021.1971289","article-title":"Global epidemiology and changing clinical presentations of invasive meningococcal disease: a narrative review","volume":"54","author":"Deghmane","year":"2022","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.vaccine.2025.127871_bb0025","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.medmal.2019.10.003","volume":"50","year":"2020","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.vaccine.2025.127871_bb0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/0272989X05284109","article-title":"Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model","volume":"26","author":"Trotter","year":"2006","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.vaccine.2025.127871_bb0035","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1016\/j.vaccine.2020.08.007","article-title":"Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: an application to England","volume":"38","author":"Beck","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127871_bb0040","series-title":"Haute Autorit\u00e9 de Sant\u00e9 [Internet]","article-title":"R\u00e9vision de la strat\u00e9gie contre les s\u00e9rogroupes ACWY et B","author":"Strat\u00e9gie de vaccination contre les infections invasives \u00e0 m\u00e9ningocoques","year":"2025"},{"key":"10.1016\/j.vaccine.2025.127871_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-20544-y","article-title":"Inferring high-resolution human mixing patterns for disease modeling","volume":"12","author":"Mistry","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.127871_bb0050","unstructured":"R\u00e9sultats d\u00e9taill\u00e9s des projections de population 2021\u20132070 pour la France \u2013 Sc\u00e9nario central \u2212 Projections de population 2021\u20132070.2024 [cited 8 Feb 2024]. Available https:\/\/www.insee.fr\/fr\/statistiques\/5894083?sommaire=5760764."},{"key":"10.1016\/j.vaccine.2025.127871_bb0055","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"a systematic review and meta-analysis","volume":"10","author":"Meningococcal carriage by age","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127871_bb0060","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1017\/S0950268805005339","article-title":"The natural history of meningococcal carriage and disease","volume":"134","author":"Trotter","year":"2006","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2025.127871_bb0065","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.127871_bb0070","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1900236","article-title":"Meningococcal B vaccine and meningococcal carriage in adolescents in Australia","volume":"382","author":"Marshall","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127871_bb0075","first-page":"17","article-title":"Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination","volume":"83","author":"Martin\u00f3n-Torres","year":"2021","journal-title":"J Inf Secur"},{"key":"10.1016\/j.vaccine.2025.127871_bb0080","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1093\/cid\/ciaa1636","article-title":"Impact of meningococcal B vaccine on invasive meningococcal disease in adolescents","volume":"73","author":"McMillan","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127871_bb0085","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1093\/cid\/ciaa1733","article-title":"Effectiveness of meningococcal vaccines at reducing invasive meningococcal disease and pharyngeal Neisseria meningitidis carriage: a systematic review and Meta-analysis","volume":"73","author":"McMillan","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127871_bb0090","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1001\/jama.2020.20449","article-title":"Association of use of a meningococcus group B vaccine with group B invasive meningococcal disease among children in Portugal","volume":"324","author":"Rodrigues","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2025.127871_bb0095","first-page":"37","article-title":"Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine","author":"Nolan","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127871_bb0100","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.vaccine.2013.09.034","article-title":"Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model","volume":"33","author":"Vickers","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127871_bb0105","first-page":"15","article-title":"The impact of aggregating serogroups in dynamic models of Neisseria meningitidis transmission","author":"Poore","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127871_bb0110","first-page":"139","article-title":"Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine","author":"Cohn","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2025.127871_bb0115","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/INF.0b013e3182054ab9","article-title":"Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age","volume":"30","author":"Baxter","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2025.127871_bb0120","series-title":"\u00c9dition nationale. Avril 2024","first-page":"34","author":"Vaccination","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127871_bb0125","series-title":"Surveillance des infections invasives \u00e0 m\u00e9ningocoque en France m\u00e9tropolitaine en 2005. \u00c9valuation quantitative par la m\u00e9thode de capture-recapture \u00e0 trois sources","author":"SPF","year":"2025"},{"key":"10.1016\/j.vaccine.2025.127871_bb0130","first-page":"564","article-title":"Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006-2015","volume":"74","author":"Parent du Chatelet","year":"2017","journal-title":"J Inf Secur"},{"key":"10.1016\/j.vaccine.2025.127871_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1011564","article-title":"Inference of transmission dynamics and retrospective forecast of invasive meningococcal disease","volume":"19","author":"Cascante-Vega","year":"2023","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.vaccine.2025.127871_bb0140","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2214-109X(16)30064-X","article-title":"Seasonal dynamics of bacterial meningitis: a time-series analysis","volume":"4","author":"Paireau","year":"2016","journal-title":"Lancet Glob Health"},{"issue":"1257","key":"10.1016\/j.vaccine.2025.127871_bb0145","first-page":"e1","article-title":"Influenza increases invasive meningococcal disease risk in temperate countries","volume":"26","author":"Salomon","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2025.127871_bb0150","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/cid\/ciab702","article-title":"Excess invasive meningococcal disease associated with seasonal influenza, South Africa, 2003-2018","volume":"74","author":"Meiring","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127871_bb0155","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2021.1996808","article-title":"Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile","author":"Gra\u00f1a","year":"2021","journal-title":"Hum Vaccin Immunother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25011685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25011685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T22:23:30Z","timestamp":1763504610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25011685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":31,"alternative-id":["S0264410X25011685"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127871","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling the impact of a quadrivalent ACWY meningococcal vaccination and vaccination targeting serogroup B in France","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127871","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127871"}}